Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis

Table 3

Summary of inhaled colistin trials.

Author	Study design	Subjects	Dose used	Outcomes	Main results
Jensen et al. [17]	RCT	𝑁=40.; Age = 7–35 years.; Inclusion criteria: chronic P. aeruginosa infection	Colistin (1 million units) BID for 3 months	Lung function (FEV1 and FVC) and clinical score	Significant improvement in clinical symptom score and pulmonary function
Day et al. [18]	Crossover study	𝑁=14.; Age = 5–16 years.; Inclusion criteria: chronic P. aeruginosa infection	Colistin (1 million units) BID for 3 months	Lung function (FEV1 and FVC), antibiotic use and hospital admissions, and symptom score	Significantly improved FEV1, FVC. Decreased antibiotic use and hospitalization, and decreased symptom score
Nikonova et al. [19]	Prospective study	𝑁=2.; Age = ≤5 years.; Inclusion criteria: chronic P. aeruginosa infection	Colistin (1 million units) BID for 3 weeks, followed till 1 year	Exacerbation rate, pulmonary symptoms	Significant improvement in the symptoms and reduced exacerbation